Q3 Earnings Forecast for aTyr Pharma Issued By HC Wainwright

aTyr Pharma, Inc. (NASDAQ:ATYR) – Equities research analysts at HC Wainwright raised their Q3 2026 EPS estimates for shares of aTyr Pharma in a report released on Monday, August 10th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.10) for the quarter, up from their prior forecast of ($0.18). The consensus estimate for aTyr Pharma’s current full-year earnings is ($0.66) per share. HC Wainwright also issued estimates for aTyr Pharma’s Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.39) EPS, FY2027 earnings at ($0.34) EPS and FY2028 earnings at ($0.38) EPS.

Several other equities research analysts also recently issued reports on ATYR. Wall Street Zen upgraded aTyr Pharma from a “sell” rating to a “hold” rating in a report on Sunday, July 12th. Freedom Capital upgraded aTyr Pharma from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 20th. Finally, Weiss Ratings cut aTyr Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $17.00.

aTyr Pharma Stock Up 1.0%

Shares of NASDAQ ATYR opened at $0.53 on Wednesday. aTyr Pharma has a twelve month low of $0.40 and a twelve month high of $6.50. The stock has a market cap of $52.38 million, a price-to-earnings ratio of -0.86 and a beta of 0.54. The company’s fifty day moving average is $0.51 and its 200-day moving average is $0.70.

aTyr Pharma (NASDAQ:ATYR) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.01. The firm had revenue of $189.56 million for the quarter.

Insiders Place Their Bets

In related news, Director Paul Schimmel bought 100,000 shares of aTyr Pharma stock in a transaction that occurred on Wednesday, May 27th. The stock was purchased at an average cost of $0.50 per share, with a total value of $50,000.00. Following the purchase, the director owned 779,143 shares in the company, valued at approximately $389,571.50. This trade represents a 14.72% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 5.75% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of ATYR. GSA Capital Partners LLP raised its position in aTyr Pharma by 272.2% in the 4th quarter. GSA Capital Partners LLP now owns 2,630,638 shares of the company’s stock valued at $2,060,000 after buying an additional 1,923,907 shares during the last quarter. California State Teachers Retirement System acquired a new position in aTyr Pharma during the 2nd quarter worth approximately $28,000. Kingswood Wealth Advisors LLC acquired a new position in aTyr Pharma during the 4th quarter worth approximately $41,000. JPMorgan Chase & Co. grew its stake in shares of aTyr Pharma by 157.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 105,817 shares of the company’s stock worth $76,000 after acquiring an additional 64,710 shares in the last quarter. Finally, ADAR1 Capital Management LLC grew its stake in shares of aTyr Pharma by 35.9% during the 4th quarter. ADAR1 Capital Management LLC now owns 50,685 shares of the company’s stock worth $40,000 after acquiring an additional 13,385 shares in the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel protein-based therapies that modulate the extracellular matrix and immune pathways. Headquartered in San Diego, California, the company applies its proprietary Extracellular Modulation® platform to identify and optimize biologic candidates for the treatment of rare and serious diseases, including pulmonary sarcoidosis, muscular dystrophy, and solid tumors.

The company’s research efforts are centered on harnessing extracellular proteins to regulate tissue remodeling, cell adhesion, and immune signaling.